Mutations in CTC may predict outcomes in some castrate-resistant prostate cancer patients
Study reveals bias among doctors who classify X-rays for coal miner’s black lung claims
26 March 2021AI used in battle against asbestos-linked cancer
26 March 2021Mutations in CTC may predict outcomes in some castrate-resistant prostate cancer patients
Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research, a journal of the American Association for Cancer Research.
